A Model for NAD(P)H:Quinoneoxidoreductase 1 (NQO1) Targeted Individualized Cancer Chemotherapy.

about

Human NAD(P)H:quinone oxidoreductase type I (hNQO1) activation of quinone propionic acid trigger groups.Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone

P2860

Q36474839-3B40F821-C453-449B-B203-46604430CC51 Q36573248-8CD1D90D-941F-4DB6-9835-2C96DC863248

P2860

A Model for NAD(P)H:Quinoneoxidoreductase 1 (NQO1) Targeted Individualized Cancer Chemotherapy.

Item

http://www.wikidata.org/entity/Q42003731

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

A Model for NAD

@nl

A Model for NAD(P)H:Quinoneoxi ...... idualized Cancer Chemotherapy.

@en

type

Item

label

A Model for NAD

@nl

A Model for NAD(P)H:Quinoneoxi ...... idualized Cancer Chemotherapy.

@en

prefLabel

A Model for NAD

@nl

A Model for NAD(P)H:Quinoneoxi ...... idualized Cancer Chemotherapy.

@en

P1476

A Model for NAD(P)H:Quinoneoxi ...... vidualized Cancer Chemotherapy

@en

P2093

Asher Begleiter

http://www.w3.org/2001/XMLSchema#string

Frank S Guziec

http://www.w3.org/2001/XMLSchema#string

Laurie Lange

http://www.w3.org/2001/XMLSchema#string

Lynn J Guziec

http://www.w3.org/2001/XMLSchema#string

Marsha K Leith

http://www.w3.org/2001/XMLSchema#string

Nadia El-Gabalawy

http://www.w3.org/2001/XMLSchema#string

P2860

Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6

Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells

Human NAD(P)H:quinone oxidoreductase (NQO1) gene structure and induction by dioxin

Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells

A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors.

Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks.

Clinical applications of quinone-containing alkylating agents.

Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cł.

Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9.

DT-diaphorase and cancer chemotherapy.

P304

1-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4137/DTI.S1146

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21904446

http://www.w3.org/2001/XMLSchema#string

P932

3086316

http://www.w3.org/2001/XMLSchema#string

A Model for NAD(P)H:Quinoneoxidoreductase 1 (NQO1) Targeted Individualized Cancer Chemotherapy.

about

P2860

P2860

A Model for NAD(P)H:Quinoneoxidoreductase 1 (NQO1) Targeted Individualized Cancer Chemotherapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932